Information on MIMETAS
MIMETAS is a global leader in the development of organ-on-a-chip products and tissue models. Recently, the company successfully secured $20.5 million in funding through a Series B financing round involving an international syndicate from Asia and Europe. MIMETAS plans to utilize the financing to accelerate its commercial expansion with the OrganoPlate® organ-on-a-chip platform. Additionally, the funding will enable the company to broaden its product portfolio, establish production capabilities for ready-to-use living tissues, and develop new OrganoPlate® products targeting clinical market segments, particularly personalized medicine. MIMETAS operates in multiple locations, including the Netherlands, the United States, and Japan.
Industry Overview in the Netherlands
The organ-on-a-chip industry is at the forefront of innovative medical research and development, providing advanced tools for pharmaceutical testing and personalized medicine. The Netherlands has positioned itself as a significant player within this sector, fostering an environment rich in scientific research and technological advancement. This has attracted numerous biotechnology firms and research institutions dedicated to exploring organ-on-a-chip technologies, advancing drug development processes while reducing reliance on animal testing.
In recent years, the Dutch government has implemented policies aimed at bolstering the life sciences and health sectors. These initiatives include funding opportunities, tax incentives, and infrastructure investment, all directed towards enhancing innovation and attracting foreign investment. Consequently, the Netherlands has become an attractive location for international biotech companies seeking to collaborate and establish a presence within Europe.
The integration of organ-on-a-chip technology into drug development signifies a shift from traditional testing methods to more predictive models that closely mimic human physiology. This shift not only accelerates the development of new drugs but also enhances the effectiveness of treatments by allowing for more personalized approaches tailored to individual patient needs. As a result, the demand for organ-on-a-chip solutions is projected to increase substantially, driving growth in this dynamic industry.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
The Rationale Behind the Deal
Furthermore, the company aims to utilize the investment to enhance its production of living tissues and diversify its offerings, enhancing its competitive edge within the market. The involvement of prominent investors indicates confidence in MIMETAS's growth potential and aligns with the increasing demand for advanced biotechnological solutions in drug development.
Information about the Investors
The investment syndicate comprises several prominent players in the biotechnology and life sciences sectors: European Life Sciences Growth Fund (ELSGF) from Singapore, Aglaia Oncology Fund II from the Netherlands, Korys from Belgium, Cathay Venture from Taiwan, and local partners InnovationQuarter and Oost NL from the Netherlands. Each investor brings unique expertise and resources, enhancing MIMETAS's growth trajectory in various markets.
ELSGF has expressed strong support for MIMETAS's innovative technology and talented team, emphasizing the company's position as a leader in the organ-on-a-chip market with substantial growth potential. Other investors, such as Korys, offer extensive experience in commercializing products at the intersection of hardware and biology, while Aglaia provides valuable clinical and oncological knowledge. Collectively, the investors are positioned to significantly influence MIMETAS’s expansion plans and market penetration efforts, particularly in the lucrative Asian markets.
View of Dealert
This investment in MIMETAS represents a strategic opportunity to be part of a pioneering technology in the biomedical space. The organ-on-a-chip market is poised for significant growth, driven by increasing demand for more effective drug testing methods and personalized treatment approaches. As a result, MIMETAS is well-placed to capitalize on these trends, offering promising potential returns for its investors.
Moreover, the quality of the investor consortium adds credibility and stability to MIMETAS's operations, providing not only capital but also strategic guidance and market access. The combination of robust technology, experienced leadership, and a supportive investor base creates a sound foundation for future success.
Given the current trajectory of the organization and its focus on expanding into clinically relevant markets, this investment could yield considerable long-term benefits. Investors can anticipate growth as the company navigates the complexities of the healthcare sector and leverages its innovative offerings to meet emerging demands. The prospects for MIMETAS seem bright, and their approach may indeed offer a rewarding investment opportunity.
Similar Deals
EQT Life Sciences, Sanofi Ventures, Roche Venture Fund → SpliceBio
2025
European Life Sciences Growth Fund, Aglaia Oncology Fund II, Korys, Cathay Venture, InnovationQuarter, Oost NL
invested in
MIMETAS
in 2018
in a Series B deal
Disclosed details
Transaction Size: $21M